Eli Lilly has signed a new research deal with BigHat Biosciences to co-develop next-generation antibody therapeutics, as the ...

Leveraging Trump’s impending tariffs, pharma companies have called on Europe again to change regulation, threatening a US ...

The ACIP has voted to recommend the use of respiratory syncytial virus (RSV) vaccines for adults aged 50 to 59.

The funding will be used to advance GLM101 into a Phase IIb trial: Credit: Malte Mueller via Getty Images. Glycomine has raised $115m in Series C financing to advance its lead investigational therapy, ...

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

Bluebird has reaffirmed its support for a proposed acquisition after Ayrmid failed to deliver a binding offer by the extended ...

The US Food and Drug Administration (FDA) has approved Neurelis’ diazepam nasal spray, Valtoco, for the short-term treatment ...

Eisai and Biogen have received marketing authorisation from the European Commission (EC) for Leqembi (lecanemab) to treat ...

One concern with in vivo CAR-Ts is the potential insertional mutagenesis of the lentiviral DNA payload, causing secondary ...

AD is a growing market with an impressive pipeline of new products from current and future players in the field.

The executive order aims to lower prescription prices, but targets the mechanism for negotiating small molecule drug costs.

Phase Ib results show VERVE-102 reduced LDL-C levels with no serious safety issues, unlike Verve’s VERVE-101 programme.